Cargando…

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose

This study characterizes antibody and T-cell immune responses over time until the booster dose of COronaVIrus Disease 2019 (COVID-19) vaccines in patients with multiple sclerosis (PwMS) undergoing different disease-modifying treatments (DMTs). We prospectively enrolled 134 PwMS and 99 health care wo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruggieri, Serena, Aiello, Alessandra, Tortorella, Carla, Navarra, Assunta, Vanini, Valentina, Meschi, Silvia, Lapa, Daniele, Haggiag, Shalom, Prosperini, Luca, Cuzzi, Gilda, Salmi, Andrea, Quartuccio, Maria Esmeralda, Altera, Anna Maria Gerarda, Garbuglia, Anna Rosa, Ascoli Bartoli, Tommaso, Galgani, Simonetta, Notari, Stefania, Agrati, Chiara, Puro, Vincenzo, Nicastri, Emanuele, Gasperini, Claudio, Goletti, Delia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218688/ https://www.ncbi.nlm.nih.gov/pubmed/37239872 http://dx.doi.org/10.3390/ijms24108525

Ejemplares similares

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Increased risk of death from COVID-19 in multiple sclerosis: A meta-analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies
por: Prosperini, Luca, et al.
Publicado: (2022)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4(+) and CD8(+) T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
por: Aiello, Alessandra, et al.
Publicado: (2022)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
por: Aiello, Alessandra, et al.
Publicado: (2022)

Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
por: Najafi-Fard, Saeid, et al.
Publicado: (2022)

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
por: Farroni, Chiara, et al.
Publicado: (2022)

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis
por: Farroni, Chiara, et al.
Publicado: (2022)

Epidemiology of HEV in the Mediterranean basin: 10-year prevalence in Italy
por: Lanini, Simone, et al.
Publicado: (2015)

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2023)

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
por: Aiello, Alessandra, et al.
Publicado: (2021)

Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects
por: Tempestilli, Massimo, et al.
Publicado: (2022)

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
por: Agrati, Chiara, et al.
Publicado: (2021)

PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease
por: Grassi, Germana, et al.
Publicado: (2021)

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
por: Santoro, Annapaola, et al.
Publicado: (2023)

Re: Remdesivir for the treatment of COVID-19 by Lee et al.
por: Beccacece, Alessia, et al.
Publicado: (2023)

Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature
por: Vita, Serena, et al.
Publicado: (2022)

Correction to: Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis
por: Tempestilli, Massimo, et al.
Publicado: (2022)

Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis
por: Tempestilli, Massimo, et al.
Publicado: (2021)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

The first case of meningitis associated with SARS-CoV-2 BA.2 variant infection with persistent viremia
por: D'Abramo, Alessandra, et al.
Publicado: (2022)

VIDAS(®) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB
por: Petruccioli, E., et al.
Publicado: (2022)

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
por: Agrati, Chiara, et al.
Publicado: (2022)

Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants
por: Alonzi, Tonino, et al.
Publicado: (2022)

Diagnostics of Ebola virus
por: Bettini, Aurora, et al.
Publicado: (2023)

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
por: Petrone, Linda, et al.
Publicado: (2021)

Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection
por: Najafi-Fard, Saeid, et al.
Publicado: (2023)

Epidemiology of Hepatitis E Virus in European Countries
por: Lapa, Daniele, et al.
Publicado: (2015)

Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
por: Ruggieri, Serena, et al.
Publicado: (2022)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021)

IP-10 detection in urine is associated with lung diseases
por: Cannas, Angela, et al.
Publicado: (2010)

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection
por: Chiacchio, Teresa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ioi1mcqghe0ejci9sdf4f3ih26